Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com

Inclusion Criteria:

- Male and female subjects ages ≥ 6 years

- Subjects resistant to corticosteroids, calcineurin inhibitors (cyclosporine and
tacrolimus), sirolimus, mycophenolate mofetil (MMF), mycophenolic acid (MPA), or
cyclophosphamide or intolerant to at least 2 of these

- UPCR ≥ 3 at screening

- FSGS or MCD confirmed by renal biopsy

- eGFR ≥ 45 for children and adults

- Concomitant use of angiotensin-converting-enzyme inhibitor (ACEi) or angiotensin
receptor blocker (ARB) at stable doses for at least 2 weeks or have intolerance
documented in the source documents maintained at the site

Exclusion Criteria:

- Kidney diseases other than FSGS or MCD

- Collapsing FSGS

- Systemic lupus erythematosus

- Diabetes mellitus, both type 1 and type 2

- Clinically significant congestive heart failure

- Post renal transplantation, including relapsing post-transplant FSGS

- Body mass index (BMI): > 40 in subjects ≥ 18 years of age and ≥ 99% percentile for
subjects < 18 years of age

Other protocol defined inclusion/exclusion criteria may apply